TPD52L2 and breast carcinoma: Conversely, in breast cancer models, TPD52L2 suppression confers metformin resistance through Pyruvate Dehydrogenase (PDH) inhibition, attenuating mitochondrial oxidative phosphorylation and ROS generation, indicating its predictive value for the metformin response [56].